Scarica l'app Stockscreener
2.99
4.91%
0.14
Dopo l'orario di chiusura:
3.04
0.05
+1.67%
Precedente Chiudi:
$2.85
Aprire:
$2.85
Volume 24 ore:
2.45M
Relative Volume:
0.68
Capitalizzazione di mercato:
$268.91M
Reddito:
$324.00K
Utile/perdita netta:
$-82.10M
Rapporto P/E:
1.4515
EPS:
2.06
Flusso di cassa netto:
$-69.18M
1 W Prestazione:
+1.36%
1M Prestazione:
+239.77%
6M Prestazione:
+235.96%
1 anno Prestazione:
+218.09%
Intervallo 1D:
$2.8005
$3.20
Intervallo di 1 settimana:
$2.705
$3.20
Portata 52W:
$0.75
$3.39
Chimerix Inc Stock (CMRX) Company Profile
Nome
Chimerix Inc
Settore
Industria
Telefono
919.806.1074
Indirizzo
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Confronta CMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
2.99 | 268.91M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-23 | Iniziato | Robert W. Baird | Outperform |
| 2022-09-07 | Iniziato | CapitalOne | Overweight |
| 2021-04-29 | Iniziato | Maxim Group | Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-31 | Iniziato | Jefferies | Buy |
| 2021-03-31 | Iniziato | Wedbush | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-02-02 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-09 | Reiterato | FBR Capital | Mkt Perform |
| 2016-02-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2016-02-23 | Reiterato | FBR Capital | Mkt Perform |
| 2016-02-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | Downgrade | Citigroup | Buy → Neutral |
| 2015-12-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-28 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | Reiterato | Piper Jaffray | Overweight |
| 2015-12-17 | Iniziato | UBS | Buy |
| 2015-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | Iniziato | Citigroup | Buy |
| 2015-08-18 | Iniziato | FBR Capital | Outperform |
| 2015-08-06 | Reiterato | Brean Capital | Buy |
| 2015-05-11 | Reiterato | Brean Capital | Buy |
| 2015-03-04 | Iniziato | Barclays | Overweight |
| 2015-02-12 | Reiterato | Stifel | Buy |
| 2014-12-31 | Reiterato | Brean Capital | Buy |
| 2014-07-08 | Ripresa | Brean Capital | Buy |
Mostra tutto
Chimerix Inc Borsa (CMRX) Ultime notizie
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest - MarketBeat
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Wedbush Weighs in on Chimerix’s Q4 Earnings (NASDAQ:CMRX) - Defense World
HC Wainwright Has Positive Outlook of Chimerix Q4 Earnings - Defense World
HC Wainwright Has Bullish Forecast for Chimerix Q4 Earnings - MarketBeat
Drugmaker seeks accelerated breakthrough for brain cancer treatment - The Business Journals
Wedbush Analysts Reduce Earnings Estimates for Chimerix - MarketBeat
Wedbush Brokers Lower Earnings Estimates for Chimerix - MarketBeat
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy (NASDAQ:CMRX) - Seeking Alpha
Chimerix (NASDAQ:CMRX) Earns Buy Rating from HC Wainwright - MarketBeat
Chimerix stock touches 52-week high at $2.20 amid market fluctuations - Investing.com Canada
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Can - GuruFocus.com
3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Dr - Asianet Newsable
S&P 500 Edges Lower; AutoZone Posts Downbeat EarningsAutoZone (NYSE:AZO), Chimerix (NASDAQ:CMRX) - Benzinga
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy - Yahoo Finance
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings - Benzinga
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? - AOL
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Dow Falls 150 Points; Oracle Posts Downbeat Results - Benzinga
Chimerix Pursues FDA Approval for Dordaviprone - TipRanks
Pre-market Movers: CMRX, CPIX, PCSA, CRDF, VRAR… - RTTNews
Chimerix Shares Top 52-week Highs, Company Plans FDA Submission of Cancer Drug Dordaviprone - MarketWatch
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End - The Manila Times
Chimerix to File FDA Application for Breakthrough Brain Cancer Drug with 28% Response Rate - StockTitan
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Drug - MSN
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Chimerix Awards Key Stock Options to New Employees in Strategic Talent Acquisition Move - StockTitan
Chimerix (FRA:CXF) Shares Outstanding (EOP) : 89.94 Mil (As of Sep. 2024) - GuruFocus.com
CMRX (Chimerix) Financial Strength : 5 (As of Sep. 2024) - GuruFocus.com
Glioma Market Size in the 7MM is approximately USD 1,000 million in 2023, estimated DelveInsight - The Globe and Mail
CMRX (Chimerix) Debt-to-EBITDA : -0.01 (As of Sep. 2024) - GuruFocus.com
Chimerix (FRA:CXF) Change In Receivables : €-0.13 Mil (TTM As of Sep. 2024) - GuruFocus.com
Wedbush Reiterates Outperform Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix (NASDAQ:CMRX) Earns Outperform Rating from Wedbush - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Chimerix updates officer severance plan, extends term - Investing.com
Chimerix (CMRX) Announces Updated Phase 2 Response Assessment of Dordaviprone - StreetInsider.com
Chimerix Cancer Drug Shows 28% Response Rate in Phase 2 Brain Tumor Trial | CMRX Stock News - StockTitan
Wedbush Reaffirms “Outperform” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Chimerix Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates - MSN
Earnings call: Chimerix reports progress and financials for Q3 2024 - Investing.com India
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - GuruFocus.com
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ... - Yahoo Finance
Chimerix: Q3 Earnings Snapshot - CT Insider
Chimerix Inc (CMRX) Quarterly 10-Q Report - Quartzy
Chimerix Inc Azioni (CMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Chimerix Inc Azioni (CMRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Andriole Michael T. | PRESIDENT AND CEO |
Aug 08 '24 |
Sale |
0.83 |
1,285 |
1,065 |
462,453 |
| Andriole Michael T. | PRESIDENT AND CEO |
Feb 14 '24 |
Sale |
1.04 |
1,744 |
1,809 |
447,021 |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER |
Feb 14 '24 |
Sale |
1.04 |
1,940 |
2,023 |
110,999 |
| Jakeman David | VP OF FINANCE AND ACCOUNTING |
Feb 14 '24 |
Sale |
1.04 |
2,660 |
2,777 |
141,232 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):